A living WHO guideline on drugs to prevent covid-19
Carregando...
Citações na Scopus
72
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Autores
LAMONTAGNE, Francois
AGORITSAS, Thomas
SIEMIENIUK, Reed
ROCHWERG, Bram
BARTOSZKO, Jessica
ASKIE, Lisa
MACDONALD, Helen
AMIN, Wagdy
BAUSCH, Frederique Jacquerioz
BURHAN, Erlina
Citação
BMJ-BRITISH MEDICAL JOURNAL, v.372, article ID n526, 5p, 2021
Resumo
CLINICAL QUESTION What is the role of drugs in preventing covid-19? WHY DOES THIS MATTER? There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. RECOMMENDATION The guideline development panel made a strong recommendation against the use of hydroxychloroquine for individuals who do not have covid-19 (high certainty). HOW THIS GUIDELINE WAS CREATED This living guideline is from the World Health Organization (WHO) and provides up to date covid-19 guidance to inform policy and practice worldwide. Magic Evidence Ecosystem Foundation (MAGIC) provided methodological support. A living systematic review with network analysis informed the recommendations. An international guideline development panel of content experts, clinicians, patients, an ethicist and methodologists produced recommendations following standards for trustworthy guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. UNDERSTANDING THE NEW RECOMMENDATION The linked systematic review and network meta-analysis (6 trials and 6059 participants) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation. The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent covid-19. UPDATES This is a living guideline. New recommendations will be published in this article and signposted by update notices to this guideline. READERS NOTE This is the first version of the living guideline for drugs to prevent covid-19. It complements the WHO living guideline on drugs to treat covid-19. When citing this article, please consider adding the update number and date of access for clarity. Drugs could be used as prophylaxis to prevent covid-19 developing in those who are free from disease. Such drugs complement vaccines that, through developing immune responses to SARS-Cov-2, reduce the risk of developing covid-19 and its consequences. Drugs to prevent covid-19 could target whole populations, those at higher risk of becoming infected with SARS-CoV-2 (due to their work, social circumstances, or a particular exposure), or those at higher risk of death and poor outcomes if infected. There are 2610 trials investigating various drug interventions for covid-19 (see section on emerging evidence).1 This rapidly evolving evidence landscape requires trustworthy interpretation and expeditious clinical practice guidelines to inform clinicians, patients, governments, ministries and health administrators. This living guideline uses emerging evidence from RCTs on drugs to prevent covid-19 and complements the livingWHOguideline on drugs to treat covid-19.(2) The living network meta-analysis associated with this guideline will incorporate new trial data and allow for analysis of comparative effectiveness.3 Details of the network meta-analysis and other related publications are listed in box 1. We will also use additional relevant evidence on long term safety, prognosis, and patient values and preferences related to covid-19 treatments to inform the living guidance.
Palavras-chave
Referências
- Abella BS, 2021, JAMA INTERN MED, V181, P195, DOI 10.1001/jamainternmed.2020.6319
- Barnabas RV, 2021, ANN INTERN MED, V174, P344, DOI 10.7326/M20-6519
- Bartoszko JJ, 2021, PROPHYLAXIS COVID 19, DOI [10.1101/2021.02.24.21250469v1, DOI 10.1101/2021.02.24.21250469V1]
- Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
- Grau-Pujol B, 2021, RES SQUARE, DOI [10.21203/rs.3.rs-72132/v1, DOI 10.21203/RS.3.RS-72132/V1]
- Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379
- Maguire Brittany J, 2020, Wellcome Open Res, V5, P60, DOI 10.12688/wellcomeopenres.15821.1
- Mitja O, 2021, NEW ENGL J MED, V384, P417, DOI 10.1056/NEJMoa2021801
- Qaseem A, 2012, ANN INTERN MED, V156, P525, DOI 10.7326/0003-4819-156-7-201204030-00009
- Rajasingham Radha, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1571
- Schreiber K, 2020, LANCET RHEUMATOL, V2, pE735, DOI 10.1016/S2665-9913(20)30382-9
- World Health Organization, 2008, HDB GUID DEV